Head of Cell and Gene Therapy Germany
Specialties includes pharmaceutical industry, marketing, and market access.
Dr. Pavlina Konstantinova is Vice President Research at uniQure, a gene therapy company focusing on orphan genetic diseases including HD.
Chief Scientific and Technological Officer
Benoit Moreaux brings 20 years of industry expertise in strategic operations planning and execution, as well as global quality assurance.
Sarah joined Celyad in 2015 to be at the offspring of a new exciting technology in the immunooncology field.
Dr. van den Bos current developed technology and IP dramatically enhancing the efficacy of mesenchymal stem cells, the productivity of cell culture media for primary cells and a novel drug target
Chief Scientific Officer
Laura Sepp-Lorenzino, Ph.D. is Chief Scientific Officer of Intellia Therapeutics. In this role, she oversees all drug research across in vivo and ex vivo (engineered cell therapy) areas.
Vice President Platform Technology
AgenTus Therapeutics Ltd
Marc van Dijk, Ph.D. leads platform development for AgenTus and Agenus, and heads the Agenus UK site.
Imperial College London
Dr Maria Papathanasiou is an appointed Lecturer at the Department of Chemical Engineering, Imperial College London (in effect April 2020).
President & Chief Executive Officer
Mr. Eric Halioua, MS, MBA, serves as President of the Board, Chief Executive Officer and President of PDC line Pharma SAS.
Managing Director/Past Chair
Life Science Group Ltd/International Serum Industry Association
Jenny has over 30 years’ experience in the cell culture industry in the UK and worldwide and a track record in building successful SMCs. Jenny is the current owner of Life Science Group Ltd (LSG).
Senior Scientist Process Development & Manufacturing
Masters in Medicine at King's College London
Founder and CEO
Dr. Karnieli earned his PhD in Biotechnology from the Sacler school of Medicine at Tel Aviv University and an MBA from the Haifa University school of management.
Troels has been part of management teams launching 3 cellular therapies across the world and raising in excess of €160 million.
Vice President Development
Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Development.
Chief Executive Officer
André acts as Chief executive Officer Director of BioPlanta GmbH and FamiCord Deutschland GmbH.
Cellular Technology Limited
Magdalena is a Co-Founding Scientist and Chief Scientific Officer for CTL and Adjunct Associate Professor of Case Western Reserve University Department of Pathology.
NxR Biotechnologies GmbH
Dr. Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland
Head, Translational Research Group
Pamela joined UCL Translational Research Office (TRO) in 2014 and has been leading the Translational Research group since 2016.
Senior Consultant in Gene and Cell Therapies
NDA Group AB
Dr Houria Bachtarzi is a Senior Consultant, Regulatory Affairs - Gene and Cell Therapies, with a strong scientific and regulatory experience in the field of advanced biological therapies
Gene Therapy and Vector Manufacturing Specialist
Miltenyi Biotec SAS
Otto-Wilhelm MERTEN has a degree in biotechnology (Ph.D.) from the University of Life Sciences in Vienna, holds an HDR at the University of Evry/Val-d’Essonne and is Visiting Professor at ITQB/UNL.
Senior Research Associate
National Institute of Biology
Work in this field is mostly performed as contract research with partners from Europe and USA
Quality Associate Director
PhD, Biomedical Science - Laboratory of Cancer Epigenetics
Director, Analytical Development for Gene Therapy
Dr. Marina Feschenko is currently a Principle Scientist at Biogen.
Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started or invested in over 40 start-up life science, technology and social enterprises
Associate Director of Vector Production
I am a classically trained chemical engineer with a deep understanding of molecular biology.
Paula M Alves holds a PhD in Biochemical Engineering from Instituto de Tecnologia Química Biológica da Universidade Nova de Lisboa.
Director, Business Development, Europe
Mio Muelthaler is on a mission to spread the news about a new fascinating disruptive nanofluidics based single-cell technology for gene therapy in EU.
Senior Director of European Public Policy
Alliance for Regenerative Medicine
Annie brings over 30 years of experience in European regulatory and government affairs, pricing, reimbursement and market access to the ARM Team.
Deputy Head, Applied Stem Cell Biology and Cell Technology
University of Leipzig
Dr. Shibashish Giri has more than 12 years’ experience in preclinical research and clinical therapy for cell, tissue and organ regeneration in Germany.
Strategic Marketing Manager
Beckman Coulter Life Sciences
Michael Kapinsky is a chemist by training.